Paysign's 2023 revenues increased 24% to $47.3M, driven by pharma patient affordability and plasma revenue growth.

Paysign, Inc. reported a 24% increase in full-year 2023 revenues to $47.3 million, with adjusted EBITDA rising by 21% to $6.7 million. The company attributed the growth to a 172% increase in pharma patient affordability revenue and a 21% rise in plasma revenue. Paysign's patient affordability business became a significant growth driver, while the company ended 2023 with 464 plasma centers and 43 active patient affordability programs.

March 26, 2024
3 Articles